Headquartered in New York City, the Americord Registry is one of the leaders in umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use. These uses include the treatment of many blood diseases, including sickle-cell anemia and leukemia.
The Americord Registry has announced that it will fund a research project by the Masonic Cancer Center at the University of Minnesota. This research will examine the potential use of donor stem cells in patients who have been previously treated for three different cancers of the blood or bone marrow; lymphoma, myeloma, or chronic lymphocytic leukemia.
Masonic Cancer Center researchers would like to use donor stem cells to further treat patients who have previously received chemotherapy. Two chemotherapeutic agents, cyclophosphamide and busulfan, for example, arrests the growth of cancer cells, and additionally, prevents the patient’s immune system from rejecting implanted stem cells from a donor. Donated stem cells, for bone marrow or umbilical cord blood, will not share the same array of cell surface proteins as the patient, and might be rejected by the patient’s immune system. However, cancer patients who have been treated with chemotherapeutic agents might be able to tolerate implanted cells, since the anti-cancer drugs might also dull the immune system to the implanted stem cells. These donated stem cells may replace the patient’s immune cells and help destroy any remaining cancer cells.
Americord has a Corporate Giving Program that was established to support research into the therapeutic uses of stem cells from umbilical cord blood, cord tissue, and placenta tissue. The funding for this research comes from Americord’s Corporate Giving Program.
“Americord is committed to supporting the advancement of stem cell treatments and technologies,” said Americord CEO Martin Smithmyer. “We are excited about the research being done at the Masonic Cancer Center and the potential it has for future treatment options.”
The study at the Masonic Cancer Center began in February 2008 and is scheduled to be completed by January 2015. It is registered with ClinicalTrials.gov in accordance with best practices and requirements of the U.S. Food and Drug Administration.